Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity. The aim of the present studies was to design a once weekly GLP-1 analogue by increasing albumin affinity and secure full stability against metabolic degradation. The fatty acid moiety and the linking chemistry to GLP-1 were the key features to secure high albumin affinity and GLP-1 receptor (GLP-1R) potency and in obtaining a prolonged exposure and action of the GLP-1 analogue. Semaglutide was selected as the optimal once weekly candidate. Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib(8), Arg(34)) and is derivatized at lysine 26. The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) was three-fold decreased compared to liraglutide, whereas the albumin affinity was increased. The plasma half-life was 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs. Semaglutide is currently in phase 3 clinical testing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The elimination half-life of 7 (Table 2), as measured after i.v. dose in minipigs, could be increased by nearly 40% through the replacement of the C18 diacid protractor with a C20 diacid (8), providing an even more attractive PK profile for potential once-weekly clinical administration when compared to the once-weekly GLP-1R agonist semaglutide [47].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [47]
In the citing paper
“We estimated the required sample size to be 60 participants (30 for oral and 30 for subcutaneous semaglutide), assuming a two-sided hypothesis test with a 95% confidence level and accounting for a potential 10% loss. This estimation was based on a minimum clinically relevant difference of -10% in fat body mass at the conclusion of the follow-up (22, 23).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [22]
In the citing paper
“Semaglutide, a GLP-1 analogue with an extended half-life of approximately 1 week (which permits once-weekly subcutaneous administration), 4”
From Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (2016) · cites this paper as [4]
In the citing paper
“The long half-life of semaglutide (approximately 7.5 hours in mice, 12 hours in rats, and 183 hours in humans) makes it suitable for once-weekly administration in humans (43, 48–50).”
From The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission (2023) · cites this paper as [48]
In the citing paper
“This formulation results in slower degradation and a half-life 155 to 184 hours, allowing for once-weekly subcutaneous dosing without compromising weight loss efficacy.(11, 26)”
From Semaglutide for the treatment of obesity (2023) · cites this paper as [26]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Schuck, P. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76713-0 · Cited by 3,868
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Fatty acid binding to plasma albumin
Spector, A. A. (1975) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36723-7 · Cited by 966
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Self-citationAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Fatty acid binding to human serum albumin: new insights from crystallographic studies
Curry, S., Brick, P., & Franks, N. P. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(99)00148-1 · Cited by 495
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Research works printed but not linked: 1
- 10.1016/s0140-6736(09)60659-0 · DOI · Paper page
Cited by
Items 801–900 of 1,000
Steenkamp, L. H., & Steenkamp, P. A. (2025) · Journal of Liquid Chromatography & Related Technologies · doi:10.1080/10826076.2025.2502034 · Cited by 2
ForePass outperforms Semaglutide in weight control, glucose metabolism, and gut microbiota in swine
Russo, S. L. M. L., Proto, L., Neto, M. G., Angelini, G., Pezzica, S., Carli, F., Previti, E., Caristo, M. E., Bove, V., Chakaroun, R., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70167 · Cited by 3
Videbæk, N., Jørgensen, L., Rieper, C. D. L., Hummelshøj, L., Petersen, S. S., Wøldike, D. B. C., & Andresen, L. O. (2025) · Bioanalysis · doi:10.1080/17576180.2025.2596576 · Cited by 3
“The fatty acid acylated to the GLP-1-derivative semaglutide mediate binding to albumin with an affinity higher than the affinity of semaglutide to the GLP-1 receptor in vitro [12].”
Zhang, X., Mao, S., Chen, X., Yang, M., Duan, J., Kennedy, J. F., & Xiao, P. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149623 · Cited by 3
Kodal, A. L. B., Ewald, J., Poulsen, C., Bonde, M. F. B., Kirchhoff, J. E., Poulsen, S., Schultz, H. S., Pedersen, K., Martis, L.-S., Kirk, R. K., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02467 · Cited by 2
Self-citationEffects of pH and Salts on the Aggregation State of Semaglutide and Membrane Filtration Performance
Duan, L., Yang, Y., Wu, H., Ding, X., & Jiang, M. (2025) · Separations · doi:10.3390/separations13010015 · Cited by 2
“The semaglutide molecule is composed of a 31-amino-acid peptide skeleton connected to fatty acid side chains, and its molecular weight is 4113.58 [5].”
InfluentialSpinelli, R., Sanchís, I., de Orellana, M., Húmpola, M. V., Rietmann, Á., & Siano, Á. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109566 · Cited by 4
Rega, M., Petraglia, F. M., D’Ursi, L., Buonocore, M., Criscuolo, D., & Santoro, A. (2026) · Clinical bioenergetics · doi:10.3390/clinbioenerg2010005 · Cited by 2
“This design extends the peptide’s half-life, enabling once-weekly injections [209,210].”
Pawlas, J. (2026) · Organic Letters · doi:10.1021/acs.orglett.6c00633 · Cited by 2
Ouyang, Q., Wu, G., Chen, A., Zhang, R., Xiao, S., Guo, D., Zhang, Q., Yan, C., Chen, X., Tang, J., et al. (2026) · Biomolecules · doi:10.3390/biom16030456 · Cited by 2
Brunel, F. M., Parlee, S. D., Li, P., Lu, W., Chabenne, J. R., Pérez–Tilve, D., Finan, B., Kharitonenkov, A., & DiMarchi, R. D. (2026) · Biochemistry · doi:10.1021/acs.biochem.5c00820 · Cited by 2
Meiners, K., Stepic, T., Meinel, L., & Lühmann, T. C. (2026) · RSC Chemical Biology · doi:10.1039/d6cb00041j · Cited by 3
“104 This optimized GLP-1 derivative was further optimized by two amino acid substitutions.”
A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide
Mao, C.-Y., Pang, Z.-J., Qiao, G., & Dong, L. (2026) · Organic Letters · doi:10.1021/acs.orglett.6c02001 · Cited by 2
Potent and biased agonists of class B1 GPCRs from a heterochiral design strategy
Gibadullin, R., Tran, L. M.-L., Niu, J., Morris, R. K., Kuhn, A. J., Mannone, J. A., Kim, T. W., Deganutti, G., & Gellman, S. H. (2026) · Nature Chemistry · doi:10.1038/s41557-026-02182-x · Cited by 2
“The collective variable (CV) ALPHARMSD 98 implemented in Plumed 2.7 99 was used to sample the helicity of peptide residues 6–29 (residues 1–5 were not considered because they are inherently more flexible than the rest of the agonist during equilibrium MD simulations).”
InfluentialKim, J.-M., Kim, K., Yu, N.-Y., Kim, D., Kang, J. Y., Baek, S.-K., Park, J., & Park, J. Y. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070770 · Cited by 2
“…glucagon-like peptide-1 (GLP-1) analog for type 2 diabetes mellitus (T2DM) management [1,2], shares significant structural similarity with the first GLP-1 analog liraglutide approved for the treatment of obesity, exhibiting a 94% homology to the native human GLP-1 amino acid sequence [3].”
Hypersensitivity Reaction to Tirzepatide With Demonstrated Tolerance to Semaglutide: A Case Report
Nejat, C., Lin, R., Addo, D., Cuenca‐Sisko, K., & Lee-Wong, M. F. (2026) · Clinical Case Reports · doi:10.1002/ccr3.73183 · Cited by 2
Wang, X., Yu, W., Liu, J., Du, J., Chen, K.-N., Hu, Q.-Q., Sun, W., & Ying, G. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.923059 · Cited by 2
Brown, L. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-73317-9_25-1 · Cited by 2
Glucagon receptor family in GtoPdb v.2023.1
BATAILLE, D., Chan, S. L. F., Delagrange, P., Drucker, D. J., Göke, B., Hills, R., Mayo, K. E., Miller, L. J., Salvatori, R., & Thorens, B. (2023) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f29/2023.1 · Cited by 2
Khamnueva, L. Y., & Андреева, Л. С. (2023) · Problems of Endocrinology · doi:10.14341/probl13245 · Cited by 3
ADVANCES TOWARD AN ORAL NON-PEPTIDE AGONIST OF THE GLP-1 RECEPTOR
Fields, T. R., Woerly, E. M., Bell, M. G., Sloop, K. W., & Ho, J. D. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch05 · Cited by 2
Wang, X., Su, Z., Du, J., Yu, W., & Sun, W. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1360506 · Cited by 2
“4) Fatty acid chain modi fi cation can increase the liposolubility of protein and peptide drugs, enhancing cell membrane permeability and facilitating transmembrane absorption (Lau et al., 2015).”
BackgroundShangguan, W., Li, X., Wang, Y., Huang, Z., Dong, Y., Feng, M., & Feng, J. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00126 · Cited by 2
Long-Circulating Vasoactive 1,18-Octadecanedioic Acid–Terlipressin Conjugate
Berger, O., Choi, W., Ko, C. H., Thompson, M. P., Avram, M. J., Scott, D. J., Hoare, B. L., Cridge, R. R., Wheatley, M., Bathgate, R. A. D., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00305 · Cited by 2
Zheng, Y., Lao, Z., Liu, R., Xu, J., Guo, L., Lin, Z., & Yang, X. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00169 · Cited by 2
Using LanM Enzymes to Modify Glucagon‐Like Peptides 1 and 2 in E.coli
Larsen, C. K., Lindquist, P., ROSENKILDE, M. M., Madsen, A. R., Haselmann, K. F., Glendorf, T., Olesen, K., Kodal, A. L. B., & Tørring, T. (2024) · ChemBioChem · doi:10.1002/cbic.202400201 · Cited by 2
“Adding a fatty acid chain to position 26 (Lys26) further increases the half-life in circulation by binding to serum albumin [26].”
BackgroundCysteinylprolyl ester-mediated drug release from a lipid–drug conjugate
Tsuji, T., Inazuki, H., Kobayashi, D., Hayashi, J., Denda, M., & Otaka, A. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129850 · Cited by 2
Impact of GLP-1 Agonists on Depression Treatment: A Literature Review
Lemieszek, P., Rudnicka, K., Sajkiewicz, I., Miga-Orczykowska, N., Jasiuk, I., Wójtowicz, J., Pustelniak, M., Krukar, K., Łukaszewska, E., Kister, K., et al. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.69.55353 · Cited by 2
Recombinant and Semisynthesis of Peptides
Fonte, P., Malcangi, A., Stucchi, M., & Oppedisano, A. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674541-00133 · Cited by 2
Current understanding and perspectives on growth and long-acting GH therapy in Japan
Hasegawa, Y., Ikegawa, K., Mitani‐Konno, M., Ariyasu, D., & Amano, N. (2024) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.2024-0058 · Cited by 2
“Notably, the technique of extending the half-life is already being employed by the same pharmaceutical company to manufacture drugs for the treatment of diabetes (65, 66).”
Alkylated RALA-Derived Peptides for Efficient Gene Delivery
Zhang, X., Zhang, Y., Rong, X., Tang, C., Liu, H., Yue, L., Su, R., Wang, Y., & Qi, W. D. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.4c01355 · Cited by 3
Semaglutide: de la moda a la evidencia científica. A propósito de una Revisión Narrativa
Bueno, E., Jara-Ruiz, E., Jara, J., Arce, M., Ramírez, A. I., & Canata, G. (2024) · Anales de la Facultad de Ciencias Médicas (Asunción) · doi:10.18004/anales/2024.057.03.102 · Cited by 2
Low Molecular-Mass Hormones: Peptidic and Steroidal Hormones
Gelves, L. G. V., Trindade, A. C. L. B., & Lima, L. M. (2024) · Topics in medicinal chemistry · doi:10.1007/7355_2024_176 · Cited by 2
Pandey, S., Kakkar, A. K., Bhadada, S. K., & Ray, S. (2025) · Discover Public Health · doi:10.1186/s12982-025-00509-6 · Cited by 3
“The higher incidence of adverse effects with semaglutide in our study may be due to its longer half-life (~ 7 days vs. ~ 13 h for liraglutide), leading to prolonged GLP-1 receptor activation [27, 28].”
Yaghmayee, S., Moazzeni, A. S., Jamialahmadi, T., Karav, S., Yaribeygi, H., Kesharwani, P., & Sahebkar, A. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.06.009 · Cited by 2
Biological and Biosimilar Medicines in Contemporary Pharmacotherapy for Metabolic Syndrome
Górecka, W., Berezovska, D., Mrozińska, M., Nowicka, G., & Czerwińska, M. E. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060768 · Cited by 2
“This modification provided semaglutide with adequate stability and extended duration of action [63].”
InfluentialSemaglutide alters behaviour and nucleus accumbens oscillatory activity in healthy mice
Mosqueira, A., Ansarifar, S., Nabavi, S., & Moreno, A. (2026) · Molecular Brain · doi:10.1186/s13041-026-01329-8 · Cited by 2
“Semaglutide 1,2 , a long-acting glucagon-like peptide-1 (GLP-1) analogue traditionally used for the treatment of diabetes, recently emerged as an efficient therapeutic agent for obesity 3–6 .”
Synthesis of a Novel PTH1–34 Analog with Increased Human Serum Albumin Affinity
Ruan, S., Dong, Y., Lu, J., Zhao, M., Lu, W., & Feng, J. (2021) · Pharmaceutical Fronts · doi:10.1055/s-0041-1731299 · Cited by 2
GLP-1 Receptor Agonists for the Treatment of Diabetes and Obesity
Palani, A., Zhou, Y., Halleck, M. M., & Carrington, P. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.13765-5 · Cited by 3
A novel thrombin-based triagonist with diabetes-protective and weight-lowering potential
Zhang, J., Zhang, Z., Ma, C., Zeng, L., Zhang, Y., Wang, P., & Xu, L. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117853 · Cited by 2
Pyrazolone ligation-mediated versatile sequential bioconjugations
Mailig, M., & Liu, F. (2020) · Chemical Science · doi:10.1039/d0sc02466j · Cited by 2
GLP ‐1 Receptor Agonists for the Treatment of Type 2 Diabetes and Obesity
Linderoth, L., Kofoed, J., Kodra, J. T., Reedtz‐Runge, S., & Kruse, T. (2021) · Wiley eBooks · doi:10.1002/9783527826872.ch3 · Cited by 3
Self-citationZhang, Q., Ruan, S., Wu, Y. J., Zhang, J.-H., Lu, J., & Feng, J. (2020) · Pharmaceutical Fronts · doi:10.1055/s-0041-1728817 · Cited by 2
Albumin-binding tag derived Exendin-4 analogue for treating hyperglycemia and diabetic complications
Xu, S., Wang, F., Li, H., Wang, Y., & Fang, D. (2021) · Bioengineered · doi:10.1080/21655979.2021.1995993 · Cited by 3
SUSTAINable management of type 2 diabetes: feasibility of use and safety of semaglutide
Shirakawa, J., & Terauchi, Y. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.01.35 · Cited by 2
“Semaglutide, a once-weekly GLP-1RA, was developed from liraglutide in the context of duration of action, stimulation of insulin secretion, and inhibition of food intake (10,11).”
BackgroundStudies on the physical stability of a C-terminally amidated variant of GLP-1
Brichtova, E. (2019) · Apollo (University of Cambridge) · doi:10.17863/cam.43927 · Cited by 2
Li, W. (2024) · Preprints.org · doi:10.20944/preprints202406.1032.v1 · Cited by 2
Li, W. (2024) · Qeios · doi:10.32388/fgtlkf · Cited by 2
Jiao, R., Lin, C., Bai, S., Cai, X., Hu, S., Lv, F., Yang, W., Zhu, X., & Ji, L. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2181693 · Cited by 1
“origin GLP-1 [24], and the receptor affinity of semaglutide is about 3 times higher than that of liraglutide [25].”
BackgroundKim, S. Q., Kim, J., Choi, M. R., Kim, J., Kim, S., & Kim, Y. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149164 · Cited by 1
Gu, J., Lao, L., Chen, Y., & Lin, S. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.118013 · Cited by 2
Weight control issues: perspectives in aesthetic medicine
Kruglova, L. S., & Вардановна, Т. А. (2024) · Medical alphabet · doi:10.33667/2078-5631-2024-25-8-12 · Cited by 1
The Novel Long-Acting Peptide S6-FA Attenuates Liver Fibrosis In Vitro and In Vivo
Li, M., Qi, L., Huang, J. Y., Li, H., Cheng, W., Shi, Z., Jiang, X., Zhou, Y., & Jiang, W. (2025) · ACS Omega · doi:10.1021/acsomega.4c10956 · Cited by 1
Lozano, F. P., Marcos, A. R., Fernández, R. C., Rodrigo, A. B., Martínez‐Hervás, S., & Ampudia‐Blasco, F. J. (2025) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2025.501574 · Cited by 1
Thome, A. D., Thonhoff, J. R., Wang, J., Berman, H., Grossman, F., & Appel, S. H. (2025) · NeuroImmune Pharmacology and Therapeutics · doi:10.1515/nipt-2025-0001 · Cited by 1
“Semaglutide is a potent and long-lasting GLP-1RA with a two amino acid sub-stitution compared to GLP-1 at Aib [8] and Arg [34] while also being derivatized at lysine residue 26 [51].”
Drug discovery technologies–Current and future trends
Noe, M. C., Steppan, C. M., & Weston, A. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00019-4 · Cited by 1
Manetto, S., Mazzoccanti, G., Bassan, M., Macis, M., Cabri, W., Ciogli, A., Ricci, A., & Gasparrini, F. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107120 · Cited by 2
Im, D., Lee, Y. E., Yoon, G., Goddard, W. A., Choi, T. S., & Kim, H. I. (2025) · Angewandte Chemie · doi:10.1002/ange.202504640 · Cited by 1
Wang, C., Wang, Y., Duan, Y., Dong, Y., Hua, H., Cui, H., Huang, S., Huang, Z., Lu, J., Ding, C., et al. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00108 · Cited by 1
Amini, A., Carlsson, J., Hakkarainen, B., Svahn, S., & Lavén, M. (2025) · Separation Science Plus · doi:10.1002/sscp.70076 · Cited by 1
Kaufmann, D., & Schlesinger, N. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17070865 · Cited by 1
“Liraglutide has a half-life of 8–10 h after intravenous and 13–15 h after SC administration, respectively [74], and can be administered up to 1.8 mg/day for T2DM and up to 3.0 mg/day for obesity [79].”
InfluentialBackbone Protecting Groups for Enhanced Peptide and Protein Synthesis
Paravizzini, S. J., Haugaard‐Kedström, L. M., Hutton, C. A., & Karas, J. A. (2025) · Angewandte Chemie · doi:10.1002/ange.202509939 · Cited by 2
Peptidic Tryptophan Halogenation by a Promiscuous Flavin‐Dependent Enzyme
Rice, A. J., Gadgil, M. G., Bisignano, P., Stein, R. A., Mchaourab, H. S., & Mitchell, D. A. (2025) · Angewandte Chemie · doi:10.1002/ange.202509729 · Cited by 1
Li, X., Qiu, Z., Xue, C., Ren, X., & Dong, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1588056 · Cited by 1
“This homology surpasses dulaglutide and signi fi cantly exceeds exenatide-based formulations and PEG loxenatide (Lund et al., 2014; Lau et al., 2015).”
Zhao, W., Niu, X., Zhou, X., Shi, R., & Zhou, X. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00007-x · Cited by 1
LiCl-driven direct synthesis of mono-protected esters from long-chain dicarboxylic fatty acids
Kuang, Y., Yang, X., Qin, T., Wang, J., Guo, P., & Jiang, C. (2025) · RSC Advances · doi:10.1039/d5ra04970a · Cited by 1
Kour, S., Pradhan, S. K., Rath, P. K., Mishra, B. P., Jena, M. K., Paital, B., Singh, S., & Sahoo, D. K. (2025) · Computational and Structural Biotechnology Reports · doi:10.1016/j.csbr.2025.100069 · Cited by 1
Rapid quantification of Semaglutide in mouse plasma: An optimized LC-MS/MS approach
Bokka, V. M., Jitta, S. R., Kolli, K., Patil, D., & Mullapudi, T. R. (2025) · Journal of the Indian Chemical Society · doi:10.1016/j.jics.2025.102276 · Cited by 1
Identification of semaglutide use through detection of U6 and U7 metabolites in human urine
Timms, M., Bowen, C., & Steel, R. (2025) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-025-06263-7 · Cited by 1
Broad‐Spectrum Antimicrobial Treatment Targeted Through Drug Conjugation to Vancomycin
Dybtved, M. S., Petersen, M. E., Firdausy, A. F., Johansen, M. I., Faddy, E., Gadeberg, C., Østergaard, L. J., Jørgensen, N. P., Glud, L. N., Søgaard, A. B., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202503932 · Cited by 1
“We also considered that albumin binding can minimize the activity of the drug at its target [43].”
Semaglutide’s Impact on Kidney Health in Obese Mice: A Metabolomics Study
Eriksson, J., & Lindgren, M. (2025) · Pharmaceutical Sciences and Drug Design · doi:10.51847/5whbt71l9k · Cited by 1
Peptide‐small Molecule Drug Conjugates for Cancer, Metabolic Diseases, and Beyond
He, R., Singh, S., & Mezo, A. R. (2025) · Peptide Science · doi:10.1002/9781119824701.ch12 · Cited by 1
Zhou, Y., Xu, P., Lu, J., Xu, S., Qiu, W., Ning, X., Xu, J., & Zheng, N. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00558 · Cited by 3
Peptide-Tools–Web Server for Calculating Physicochemical Properties of Peptides
Frolov, A. I., Morley, J., dos Santos, A. G., Genapathy, S., & Ghiandoni, G. M. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c02296 · Cited by 3
Selective N‐Terminal Modification of Peptides and Proteins Using Fatty Acyl Phosphates
Pérez, L. R., King, T. A., Finnigan, W., Angelastro, A., Cain, K. M., Eldrid, C., Houghton, J. W., Tate, E. W., Barran, P. E., Goundry, W. R. F., et al. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.202513289 · Cited by 1
Shah, P. P., & Bhattacharya, R. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101418 · Cited by 2
“1 , Panel B) [15,16] The take-home message for patients is that these drugs are 98-99 % identical to our natural hormones; the modifications simply make them work better as medicines.”
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Management of Diabetes Mellitus: A Review
Singh, V., Yadav, V., Awasthi, V., Yadav, R., Shukla, S., Gupta, D., & Shukla, A. K. (2025) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.4.6.15 · Cited by 1
Li, X., Yang, T., Lei, S., Jiang, X. Y., Zhu, S., Li, X., Ding, M., Tang, W., & Lu, W. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00728 · Cited by 1
Correra, A., Mauriello, A., Cetoretta, V., Maratea, A. C., Riegler, L., Sarno, I. D., Giallauria, F., Guerra, F., Russo, V., & D’Andrea, A. (2026) · Pharmaceuticals · doi:10.3390/ph19020297 · Cited by 3
“Glucagon-like peptide-1 receptor agonists (GLP-1RA) have emerged as a pivotal class of treatment, as they enhance insulin secretion and suppress glucagon release in a glucose-dependent manner [2].”
Chen, C., Wong, M.-T., Yu, Y., Chu, H., Lim, C., & Chang, T. W. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126752 · Cited by 1
Brain shuttle peptides: From permeability assay toolbox to data-driven discovery
Mohovic, N., Njirjak, M., Dražić, E., Janković, P., & Kalafatović, D. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.02.002 · Cited by 1
Cetiner, S. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02232-y · Cited by 1
Song, S., Hyeon, M., Kim, S., Kang, Y., Hahm, S., Park, E. W., Shin, B. S., & Shin, S. (2026) · Journal of Analytical Science & Technology · doi:10.1186/s40543-026-00540-5 · Cited by 1
Dayel, F. F. B., Alanazi, R. J., Alenazi, M. A., Alkhalifah, S., Dayel, D. F. B., Mawkili, W., & Alwhaibi, A. M. (2026) · Healthcare · doi:10.3390/healthcare14070845 · Cited by 1
“Semaglutide was designed for once-weekly administration owing to its long-acting, fatty acid-conjugated structure that significantly prolonged its half-life [5,6].”
Glucagon-like peptide-1 drugs, gastrointestinal function and critical illness
Nadkarni, A., Deane, A. M., & Plummer, M. P. (2026) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001376 · Cited by 3
Song, S., Kim, J., Kim, S., Shin, B. S., & Shin, S. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119345 · Cited by 2
Xu, X.-J., Shen, K., Ma, Y., Zhang, X.-L., Wang, Q., Liu, P., He, Q.-F., Wang, X., Xu, Y.-N., Fu, H.-L., et al. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116666 · Cited by 2
Zhou, S., Zhu, M., Zhu, J., Zhang, L., Feng, X., Hu, H., & Liu, Y. (2026) · Chinese Chemical Letters · doi:10.1016/j.cclet.2026.112886 · Cited by 1
Discovery of a High-Potency Balanced GLP-1/GIP Dual Agonist by Molecular Dynamics Evolution
Zhang, N., Teng, L., Yu, X., Wang, Z., Zhang, Z., Dong, Z., & Liu, D. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00466 · Cited by 1
Multicomponent Stapling of Glucagon‐Like Peptide‐1 Enables Receptor‐Guided PROTAC Delivery
Venne, J. L., Krajčovičová, S., Davies, G., Bolt, H., Revell, J. D., & Spring, D. R. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.9595531 · Cited by 1
Evidence-informed guidance for the clinical use of oral semaglutide in obesity management
Rubino, D., Wharton, S., Knight, M. G., & Aroda, V. R. (2026) · Postgraduate Medicine · doi:10.1080/00325481.2026.2686467 · Cited by 1
“The GLP-1RA semaglutide is a therapeutic peptide that was originally developed as a subcutaneous formulation to ensure adequate bioavailability [18,19].”
qi, Q., gao, G., Li, G., & Bian, X. (2026) · PLoS ONE · doi:10.1371/journal.pone.0348509 · Cited by 2
“The new strategy significantly improves production yield compared to previous strategies [14,23–27].”
Dong, Y. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s637327 · Cited by 1
Semaglutide for Refractory Reactive Hypoglycaemia: A Case Report
Kalimuthu, H., Seekkuge, G., & Joseph, S. (2026) · Cureus · doi:10.7759/cureus.112861 · Cited by 1
Santoro, A., Macis, M., D’Ursi, A. M., & Ricci, A. (2026) · Molecules · doi:10.3390/molecules31152556 · Cited by 1
“Structural analyses indicated that a longer acyl chain increases albumin affinity and mitigates excessive aggregation, favoring reversible assembly dynamics [22].”
Brubaker, J., Kim, S.-K., Li, B., Yang, M. Y., & Goddard, W. A. (2026) · Medicinal Chemistry Research · doi:10.1007/s00044-026-03579-6 · Cited by 1
“Among the four ligand-GLP-1R-Gs complexes analyzed, semaglutide has been reported as a balanced (non-biased) agonist, activating both of these signaling pathways with comparable efficacy [ 24, 29].”
Impact of Amphiphilic Balance on Nano–Bio Interactions of Peptide Amphiphile Nanostructures
Bonic, K., Mooney, K., Xiang, L., Esener, S., & Yıldırım, A. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6c09708 · Cited by 1
Nature-inspired macrocyclic peptides: Discovery and molecular engineering for drug development
Bergamaschi, G., Lodigiani, G., Gandolfi, S., Sargsyan, T. H., & Gori, A. (2026) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2026.102738 · Cited by 1
Vignera, S. L., & Condorelli, R. A. (2026) · Pharmaceuticals · doi:10.3390/ph19081236 · Cited by 1
“The development of glucagon-like peptide-1 receptor agonists (GLP-1RAs) has transformed the obesity pharmacotherapy landscape, offering both meaningful weight reduction and favourable cardiometabolic effects [3,4].”
Peng, S., Lindley, A. A., Sturchio, N. C., & Hatzinger, P. B. (2026) · Journal of Geoscience and Environment Protection · doi:10.4236/gep.2026.149010 · Cited by 2
Metadata
- Authors
- Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., Strauss, H. M., Gram, D. X., Knudsen, S. M., Nielsen, F. S., Thygesen, P., Reedtz-Runge, S., & Kruse, T.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Global Research, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark
- Corresponding author
- Lau, Jesper
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-09-11
- Volume
- 58
- Issue
- 18
- Pages
- 7370-7380
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2162140339
- Cited by
- 1,105
- References
- 36
- Citations by year
- 2026: 160 · 2025: 193 · 2024: 151 · 2023: 97 · 2022: 106 · 2021: 84 · 2020: 88 · 2019: 71 · 2018: 77 · 2017: 46 · 2016: 30 · 2015: 2
- FWCI
- 44.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- semaglutide, liraglutide, glucagon-like peptide-1 analogues, GLP-1 receptor, albumin binding, weekly dosing, plasma half-life, metabolic stability, fatty acid acylation, type 2 diabetes, obesity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Animals, Cell Line, Glucagon-Like Peptides, Half-Life, Cricetinae, Humans, Injections, Subcutaneous, Male, Mice, Obese, Models, Molecular, Structure-Activity Relationship, Swine, Swine, Miniature, Rats, Sprague-Dawley, Crystallography, X-Ray, Glucagon-Like Peptide 1, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.